OCSTAMP
gene geneOn this page
Also known as dJ257E24.3
Summary
OCSTAMP (osteoclast stimulatory transmembrane protein, HGNC:16116) is a protein-coding gene on chromosome 20q13.12, encoding Osteoclast stimulatory transmembrane protein (Q9BR26). Probable cell surface receptor that plays a role in cellular fusion and cell differentiation.
The protein encoded by this gene is orthologous to the mouse osteoclast stimulatory transmembrane protein (OCSTAMP), which is a membrane-anchored cell surface receptor that promotes nucleation of osteoclasts. The mouse protein is also involved in bone resorption and osteoclast differentiation.
Source: NCBI Gene 128506 — RefSeq curated summary.
At a glance
- GWAS associations: 4
- Clinical variants (ClinVar): 86 total
- MANE Select transcript:
NM_080721
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:16116 |
| Approved symbol | OCSTAMP |
| Name | osteoclast stimulatory transmembrane protein |
| Location | 20q13.12 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | dJ257E24.3 |
| Ensembl gene | ENSG00000149635 |
| Ensembl biotype | protein_coding |
| OMIM | 620432 |
| Entrez | 128506 |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 protein_coding
ENST00000279028
RefSeq mRNA: 1 — MANE Select: NM_080721
NM_080721
CCDS: CCDS54468
Canonical transcript exons
ENST00000279028 — 3 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000991715 | 46545327 | 46546329 |
| ENSE00000991716 | 46540946 | 46541927 |
| ENSE00001703184 | 46550517 | 46550654 |
Expression profiles
Bgee: expression breadth tissue_specific, 6 present calls, max score 44.35.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.4920 / max 172.1297, expressed in 111 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 187571 | 1.4920 | 111 |
Top tissues by expression
117 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| bone marrow cell | CL:0002092 | 44.35 | gold quality |
| sural nerve | UBERON:0015488 | 37.66 | gold quality |
| colonic epithelium | UBERON:0000397 | 37.20 | gold quality |
| bone marrow | UBERON:0002371 | 37.06 | gold quality |
| duodenum | UBERON:0002114 | 37.00 | gold quality |
| ventricular zone | UBERON:0003053 | 36.48 | gold quality |
| cortical plate | UBERON:0005343 | 36.47 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 35.29 | gold quality |
| lymph node | UBERON:0000029 | 33.85 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 33.38 | gold quality |
| adult mammalian kidney | UBERON:0000082 | 32.56 | silver quality |
| muscle tissue | UBERON:0002385 | 32.37 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 32.15 | gold quality |
| kidney | UBERON:0002113 | 32.03 | silver quality |
| mucosa of stomach | UBERON:0001199 | 32.01 | gold quality |
| liver | UBERON:0002107 | 30.44 | gold quality |
| adrenal tissue | UBERON:0018303 | 30.09 | gold quality |
| stromal cell of endometrium | CL:0002255 | 29.87 | gold quality |
| vermiform appendix | UBERON:0001154 | 29.26 | gold quality |
| substantia nigra | UBERON:0002038 | 29.15 | silver quality |
| islet of Langerhans | UBERON:0000006 | 29.07 | gold quality |
| monocyte | CL:0000576 | 28.57 | gold quality |
| leukocyte | CL:0000738 | 28.48 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 28.38 | silver quality |
| metanephros cortex | UBERON:0010533 | 27.93 | gold quality |
| Ammon’s horn | UBERON:0001954 | 27.90 | gold quality |
| placenta | UBERON:0001987 | 27.54 | gold quality |
| primary visual cortex | UBERON:0002436 | 27.39 | gold quality |
| blood | UBERON:0000178 | 26.88 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 26.87 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 1.47 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
14 targeting OCSTAMP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-433-3P | 99.98 | 69.37 | 1203 |
| HSA-MIR-1827 | 99.63 | 68.57 | 3265 |
| HSA-MIR-1252-3P | 99.55 | 67.71 | 2862 |
| HSA-MIR-766-5P | 99.47 | 67.91 | 2225 |
| HSA-MIR-1304-5P | 98.90 | 68.58 | 1054 |
| HSA-MIR-5011-3P | 98.63 | 64.81 | 638 |
| HSA-MIR-665 | 97.60 | 65.64 | 1781 |
| HSA-MIR-625-3P | 97.32 | 66.55 | 554 |
| HSA-MIR-2278 | 97.30 | 66.19 | 1130 |
| HSA-MIR-3121-5P | 97.30 | 66.62 | 1146 |
| HSA-MIR-6082 | 96.40 | 70.86 | 216 |
| HSA-MIR-877-5P | 94.62 | 66.30 | 710 |
| HSA-MIR-4732-5P | 90.07 | 64.77 | 412 |
Literature-anchored findings (GeneRIF, showing 2)
- Results indicte that oc-stamp may play an important role in macrophage polarization and inhibit the M1 pro-inflammatory state. (PMID:28981605)
- Osteoclast stimulatory transmembrane protein (OC-STAMP) is a promising molecular prognostic indicator for multiple myeloma. (PMID:32282962)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | ocstamp | ENSDARG00000022139 |
| mus_musculus | Ocstamp | ENSMUSG00000027670 |
| rattus_norvegicus | Ocstamp | ENSRNOG00000019110 |
Paralogs (3): DCST2 (ENSG00000163354), DCST1 (ENSG00000163357), DCSTAMP (ENSG00000164935)
Protein
Protein identifiers
Osteoclast stimulatory transmembrane protein — Q9BR26 (reviewed: Q9BR26)
All UniProt accessions (1): Q9BR26
UniProt curated annotations — full annotation on UniProt →
Function. Probable cell surface receptor that plays a role in cellular fusion and cell differentiation. Cooperates with DCSTAMP in modulating cell-cell fusion in both osteoclasts and foreign body giant cells (FBGCs). Involved in osteoclast bone resorption. Promotes osteoclast differentiation and may play a role in the multinucleated osteoclast maturation.
Subcellular location. Membrane.
RefSeq proteins (1): NP_542452* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR012858 | DC_STAMP-like | Domain |
| IPR051856 | CSR-E3_Ligase_Protein | Family |
Pfam: PF07782
UniProt features (15 total): topological domain 7, transmembrane region 6, chain 1, sequence variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9BR26-F1 | 74.40 | 0.34 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 88 (showing top):
GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_REGULATION_OF_OSTEOCLAST_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_HEMOPOIESIS, GOBP_RESPONSE_TO_PEPTIDE, GOBP_MYELOID_LEUKOCYTE_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_REGULATION_OF_LEUKOCYTE_DIFFERENTIATION, GOBP_REGULATION_OF_HEMOPOIESIS, GOBP_LEUKOCYTE_PROLIFERATION, GOBP_CELLULAR_RESPONSE_TO_HORMONE_STIMULUS, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM3, GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_OSTEOCLAST_DIFFERENTIATION, GOBP_REGULATION_OF_SYNCYTIUM_FORMATION_BY_PLASMA_MEMBRANE_FUSION
GO Biological Process (7): positive regulation of macrophage fusion (GO:0034241), positive regulation of osteoclast differentiation (GO:0045672), cellular response to tumor necrosis factor (GO:0071356), cellular response to estrogen stimulus (GO:0071391), multinuclear osteoclast differentiation (GO:0072674), positive regulation of osteoclast proliferation (GO:0090290), cell differentiation (GO:0030154)
GO Molecular Function (0):
GO Cellular Component (1): membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| osteoclast differentiation | 2 |
| macrophage fusion | 1 |
| regulation of macrophage fusion | 1 |
| positive regulation of syncytium formation by plasma membrane fusion | 1 |
| positive regulation of myeloid leukocyte differentiation | 1 |
| regulation of osteoclast differentiation | 1 |
| response to tumor necrosis factor | 1 |
| cellular response to cytokine stimulus | 1 |
| cellular response to hormone stimulus | 1 |
| response to estrogen | 1 |
| osteoclast proliferation | 1 |
| positive regulation of leukocyte proliferation | 1 |
| regulation of osteoclast proliferation | 1 |
| cellular developmental process | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
286 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| OCSTAMP | DCSTAMP | Q9H295 | 930 |
| OCSTAMP | ATP6V0D2 | Q8N8Y2 | 774 |
| OCSTAMP | NFATC1 | O95644 | 750 |
| OCSTAMP | CTSK | P43235 | 738 |
| OCSTAMP | ACP5 | P13686 | 699 |
| OCSTAMP | TNFSF11 | O14788 | 673 |
| OCSTAMP | OSCAR | Q8IYS5 | 649 |
| OCSTAMP | MMP9 | P14780 | 615 |
| OCSTAMP | CALCR | P30988 | 536 |
| OCSTAMP | DCST1 | Q5T197 | 485 |
| OCSTAMP | FOS | P01100 | 478 |
| OCSTAMP | TRAF6 | Q9Y4K3 | 452 |
| OCSTAMP | CLCN7 | P51798 | 444 |
| OCSTAMP | ITGB3 | P05106 | 427 |
| OCSTAMP | CSF1 | P09603 | 408 |
IntAct
0 interactions, top by confidence:
ESM2 similar proteins: A0JN53, A0PJX8, A1L1L2, A1L3T7, A4FV45, B0BMG8, E2JF22, G3HQ82, O15360, O43299, O70491, P60330, Q0KL00, Q0V8E7, Q17Q97, Q24JP3, Q3U829, Q49LS3, Q4QR83, Q562E7, Q5ND34, Q5R7B4, Q5T1A1, Q5XG04, Q6NUQ4, Q6PH58, Q6UX68, Q7L4E1, Q7Z412, Q8BGI5, Q8BM55, Q8BSD4, Q8BXV2, Q8C3R1, Q8C7B8, Q8IXR5, Q8K0R6, Q8N6S5, Q8R115, Q8VCA6
Diamond homologs: Q9BR26, Q9D611
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
86 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 77 |
| Likely benign | 8 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
444 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 20:46541924:CCAC:C | acceptor_gain | 1.0000 |
| 20:46541925:CAC:C | acceptor_gain | 1.0000 |
| 20:46541925:CACC:C | acceptor_gain | 1.0000 |
| 20:46541927:CCT:C | acceptor_gain | 1.0000 |
| 20:46541927:CCTT:C | acceptor_loss | 1.0000 |
| 20:46541928:CTTGG:C | acceptor_loss | 1.0000 |
| 20:46541929:T:A | acceptor_loss | 1.0000 |
| 20:46541929:T:C | acceptor_gain | 1.0000 |
| 20:46541929:T:TC | acceptor_gain | 1.0000 |
| 20:46541923:GCCAC:G | acceptor_gain | 0.9900 |
| 20:46541924:CCACC:C | acceptor_gain | 0.9900 |
| 20:46541928:C:CC | acceptor_gain | 0.9900 |
| 20:46545335:TG:T | donor_gain | 0.9900 |
| 20:46545325:A:AC | donor_gain | 0.9800 |
| 20:46545326:C:CC | donor_gain | 0.9800 |
| 20:46545326:CAT:C | donor_gain | 0.9800 |
| 20:46541928:C:T | acceptor_gain | 0.9700 |
| 20:46549303:T:C | donor_gain | 0.9700 |
| 20:46541926:AC:A | acceptor_gain | 0.9600 |
| 20:46545320:CACT:C | donor_loss | 0.9500 |
| 20:46545321:ACTTA:A | donor_loss | 0.9500 |
| 20:46545322:CTTAC:C | donor_loss | 0.9500 |
| 20:46545323:TTA:T | donor_loss | 0.9500 |
| 20:46545324:TACAT:T | donor_loss | 0.9500 |
| 20:46545325:A:T | donor_loss | 0.9500 |
| 20:46545326:C:CA | donor_loss | 0.9500 |
| 20:46542663:ATGT:A | donor_gain | 0.9400 |
| 20:46545332:A:AC | donor_gain | 0.9400 |
| 20:46545333:C:CC | donor_gain | 0.9400 |
| 20:46549302:A:AC | donor_gain | 0.9400 |
AlphaMissense
3580 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 20:46545612:A:C | F254L | 0.975 |
| 20:46545612:A:T | F254L | 0.975 |
| 20:46545614:A:G | F254L | 0.975 |
| 20:46545402:G:C | F324L | 0.970 |
| 20:46545402:G:T | F324L | 0.970 |
| 20:46545404:A:G | F324L | 0.970 |
| 20:46541676:G:C | F433L | 0.956 |
| 20:46541676:G:T | F433L | 0.956 |
| 20:46541678:A:G | F433L | 0.956 |
| 20:46541673:G:C | F434L | 0.953 |
| 20:46541673:G:T | F434L | 0.953 |
| 20:46541675:A:G | F434L | 0.953 |
| 20:46545996:G:C | S126R | 0.951 |
| 20:46545996:G:T | S126R | 0.951 |
| 20:46545998:T:G | S126R | 0.951 |
| 20:46541835:C:A | W380C | 0.943 |
| 20:46541835:C:G | W380C | 0.943 |
| 20:46545951:G:C | N141K | 0.942 |
| 20:46545951:G:T | N141K | 0.942 |
| 20:46545606:A:C | N256K | 0.938 |
| 20:46545606:A:T | N256K | 0.938 |
| 20:46546047:G:C | S109R | 0.937 |
| 20:46546047:G:T | S109R | 0.937 |
| 20:46546049:T:G | S109R | 0.937 |
| 20:46545923:A:G | C151R | 0.922 |
| 20:46541904:G:C | F357L | 0.917 |
| 20:46541904:G:T | F357L | 0.917 |
| 20:46541906:A:G | F357L | 0.917 |
| 20:46545897:A:C | S159R | 0.913 |
| 20:46545897:A:T | S159R | 0.913 |
dbSNP variants (sampled 300 via entrez): RS1000137103 (20:46552544 C>G), RS1000173141 (20:46550749 C>T), RS1000203180 (20:46549582 A>T), RS1000356828 (20:46546773 C>A,G), RS1000693130 (20:46545652 G>A,C,T), RS1001219080 (20:46543795 A>G,T), RS1001507774 (20:46547706 A>G), RS1001594246 (20:46544169 T>G), RS1001755140 (20:46549639 A>C), RS1001843150 (20:46546121 CA>C), RS1001954565 (20:46552429 T>C), RS1002104783 (20:46546381 T>A,C,G), RS1002145182 (20:46549967 T>G), RS1002730156 (20:46541554 G>A), RS1003212695 (20:46545554 G>A,T)
Disease associations
OMIM: gene MIM:620432 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
4 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST005956_29 | Waist-to-hip ratio adjusted for BMI | 4.000000e-10 |
| GCST005957_10 | Waist-to-hip ratio adjusted for BMI (age <50) | 5.000000e-06 |
| GCST005958_17 | Waist-to-hip ratio adjusted for BMI (age >50) | 3.000000e-06 |
| GCST005962_25 | Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test) | 1.000000e-09 |
EFO canonical traits (3, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0007788 | BMI-adjusted waist-hip ratio |
| EFO:0008007 | age at assessment |
| EFO:0008343 | sex interaction measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
7 total (human), top 7 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| aflatoxin B2 | increases methylation | 1 |
| Resveratrol | affects cotreatment, decreases expression | 1 |
| Leflunomide | increases expression | 1 |
| Benzo(a)pyrene | affects methylation | 1 |
| Cholesterol | increases expression | 1 |
| Malathion | increases expression | 1 |
| Plant Extracts | affects cotreatment, decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.